Cargando…

Growing Impact of Restenosis on the Surgical Treatment of Peripheral Arterial Disease

BACKGROUND: Patients with peripheral arterial disease often experience treatment failure from restenosis at the site of a prior peripheral endovascular intervention (PVI) or lower extremity bypass (LEB). The impact of these treatment failures on the utilization and outcomes of secondary intervention...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Douglas W., Schanzer, Andres, Zhao, Yuanyuan, MacKenzie, Todd A., Nolan, Brian W., Conte, Michael S., Goodney, Philip P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886769/
https://www.ncbi.nlm.nih.gov/pubmed/24275626
http://dx.doi.org/10.1161/JAHA.113.000345
_version_ 1782478920414658560
author Jones, Douglas W.
Schanzer, Andres
Zhao, Yuanyuan
MacKenzie, Todd A.
Nolan, Brian W.
Conte, Michael S.
Goodney, Philip P.
author_facet Jones, Douglas W.
Schanzer, Andres
Zhao, Yuanyuan
MacKenzie, Todd A.
Nolan, Brian W.
Conte, Michael S.
Goodney, Philip P.
author_sort Jones, Douglas W.
collection PubMed
description BACKGROUND: Patients with peripheral arterial disease often experience treatment failure from restenosis at the site of a prior peripheral endovascular intervention (PVI) or lower extremity bypass (LEB). The impact of these treatment failures on the utilization and outcomes of secondary interventions is poorly understood. METHODS AND RESULTS: In our regional vascular quality improvement collaborative, we compared 2350 patients undergoing primary infrainguinal LEB with 1154 patients undergoing secondary infrainguinal LEB (LEB performed after previous revascularization in the index limb) between 2003 and 2011. The proportion of patients undergoing secondary LEB increased by 72% during the study period (22% of all LEBs in 2003 to 38% in 2011, P<0.001). In‐hospital outcomes, such as myocardial infarction, death, and amputation, were similar between primary and secondary LEB groups. However, in both crude and propensity‐weighted analyses, secondary LEB was associated with significantly inferior 1‐year outcomes, including major adverse limb event‐free survival (composite of death, new bypass graft, surgical bypass graft revision, thrombectomy/thrombolysis, or above‐ankle amputation; Secondary LEB MALE‐free survival = 61.6% vs primary LEB MALE‐free survival = 67.5%, P=0.002) and reintervention or amputation‐free survival (composite of death, reintervention, or above‐ankle amputation; Secondary LEB RAO‐free survival = 58.9% vs Primary LEB RAO‐free survival 64.1%, P=0.003). Inferior outcomes for secondary LEB were observed regardless of the prior failed treatment type (PVI or LEB). CONCLUSIONS: In an era of increasing utilization of PVI, a growing proportion of patients undergo LEB in the setting of a prior failed PVI or surgical bypass. When caring for patients with peripheral arterial disease, physicians should recognize that first treatment failure (PVI or LEB) affects the success of subsequent revascularizations.
format Online
Article
Text
id pubmed-3886769
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-38867692014-01-10 Growing Impact of Restenosis on the Surgical Treatment of Peripheral Arterial Disease Jones, Douglas W. Schanzer, Andres Zhao, Yuanyuan MacKenzie, Todd A. Nolan, Brian W. Conte, Michael S. Goodney, Philip P. J Am Heart Assoc Original Research BACKGROUND: Patients with peripheral arterial disease often experience treatment failure from restenosis at the site of a prior peripheral endovascular intervention (PVI) or lower extremity bypass (LEB). The impact of these treatment failures on the utilization and outcomes of secondary interventions is poorly understood. METHODS AND RESULTS: In our regional vascular quality improvement collaborative, we compared 2350 patients undergoing primary infrainguinal LEB with 1154 patients undergoing secondary infrainguinal LEB (LEB performed after previous revascularization in the index limb) between 2003 and 2011. The proportion of patients undergoing secondary LEB increased by 72% during the study period (22% of all LEBs in 2003 to 38% in 2011, P<0.001). In‐hospital outcomes, such as myocardial infarction, death, and amputation, were similar between primary and secondary LEB groups. However, in both crude and propensity‐weighted analyses, secondary LEB was associated with significantly inferior 1‐year outcomes, including major adverse limb event‐free survival (composite of death, new bypass graft, surgical bypass graft revision, thrombectomy/thrombolysis, or above‐ankle amputation; Secondary LEB MALE‐free survival = 61.6% vs primary LEB MALE‐free survival = 67.5%, P=0.002) and reintervention or amputation‐free survival (composite of death, reintervention, or above‐ankle amputation; Secondary LEB RAO‐free survival = 58.9% vs Primary LEB RAO‐free survival 64.1%, P=0.003). Inferior outcomes for secondary LEB were observed regardless of the prior failed treatment type (PVI or LEB). CONCLUSIONS: In an era of increasing utilization of PVI, a growing proportion of patients undergo LEB in the setting of a prior failed PVI or surgical bypass. When caring for patients with peripheral arterial disease, physicians should recognize that first treatment failure (PVI or LEB) affects the success of subsequent revascularizations. Blackwell Publishing Ltd 2013-12-19 /pmc/articles/PMC3886769/ /pubmed/24275626 http://dx.doi.org/10.1161/JAHA.113.000345 Text en © 2013 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Jones, Douglas W.
Schanzer, Andres
Zhao, Yuanyuan
MacKenzie, Todd A.
Nolan, Brian W.
Conte, Michael S.
Goodney, Philip P.
Growing Impact of Restenosis on the Surgical Treatment of Peripheral Arterial Disease
title Growing Impact of Restenosis on the Surgical Treatment of Peripheral Arterial Disease
title_full Growing Impact of Restenosis on the Surgical Treatment of Peripheral Arterial Disease
title_fullStr Growing Impact of Restenosis on the Surgical Treatment of Peripheral Arterial Disease
title_full_unstemmed Growing Impact of Restenosis on the Surgical Treatment of Peripheral Arterial Disease
title_short Growing Impact of Restenosis on the Surgical Treatment of Peripheral Arterial Disease
title_sort growing impact of restenosis on the surgical treatment of peripheral arterial disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3886769/
https://www.ncbi.nlm.nih.gov/pubmed/24275626
http://dx.doi.org/10.1161/JAHA.113.000345
work_keys_str_mv AT jonesdouglasw growingimpactofrestenosisonthesurgicaltreatmentofperipheralarterialdisease
AT schanzerandres growingimpactofrestenosisonthesurgicaltreatmentofperipheralarterialdisease
AT zhaoyuanyuan growingimpactofrestenosisonthesurgicaltreatmentofperipheralarterialdisease
AT mackenzietodda growingimpactofrestenosisonthesurgicaltreatmentofperipheralarterialdisease
AT nolanbrianw growingimpactofrestenosisonthesurgicaltreatmentofperipheralarterialdisease
AT contemichaels growingimpactofrestenosisonthesurgicaltreatmentofperipheralarterialdisease
AT goodneyphilipp growingimpactofrestenosisonthesurgicaltreatmentofperipheralarterialdisease
AT growingimpactofrestenosisonthesurgicaltreatmentofperipheralarterialdisease